✦ LIBER ✦

Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer

✍ Scribed by Christian Manegold; Gabriele Koschel; Dagmar Hruska; Kathrin Schott-von-Römer; Jörg Mezger; Lothar Richard Pilz

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-20 Docetaxel and gemcitabine as second

✍ Bernardo, Maria Manuela; Sousa, Manuel; Nunes, Orlando; Gonçalves, Antonio; Mato 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Gemcitabine plus docetaxel as first-line

✍ Joaquín Casal; Margarita Amenedo; José Ramón Mel; Luis Miguel Antón; Rubén Rodrí 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 343 KB

Phase II trial of weekly docetaxel and g

✍ Sujith Kalmadi; Giles McNeill; Mellar Davis; David Peereboom; David Adelstein; T 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 68 KB

A randomized phase III study of the doce

✍ Athanasios G Pallis; Sophia Agelaki; Athina Agelidou; Ioannis Varthalitis; Kosta 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 359 KB

First-Line Single Agent Treatment With G

✍ Niho, S. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 124 KB

Second-line treatment with single-agent

✍ van Putten, J.W.G; Baas, P; Codrington, H; Kwa, H.B; Groen, H.J.M 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 108 KB